The World's Definitive Degrader & Proximity-Based Drugs Event

This Event Has Now Run

Thank you to our speakers, sponsors, and delegates who joined us in Boston! If you are interested in the 2026 event, please get in touch at: info@hansonwade.com

Accelerating the Discovery, Development & Approval of First-In-Class Selective, Safe & Efficacious Degraders & Proximity-Based Drugs to Target the Undruggable

As the TPD field eagerly awaits the approval of Arvinas’s Vepdegestrant, and with C4 Therapeutics and Kymera progressing through Phase 1 and 2 clinical trials, 2025 was poised to be the year of clinical validation for TPD. This has been echoed in the flurry of partnerships worth over $200M in 2025 alone, with the majority of big pharma now invested in molecular glues, PROTACs, or novel induced proximity drugs.

Returning as the industry’s definitive forum from early discovery to clinical development, the Annual TPD & Induced Proximity Summit is the world’s largest and longest-standing forum for proximity-based modalities, enabling you to fully immerse yourself in the breadth and depth of cutting-edge induced proximity therapeutic development.

2025 Summit featured key leaders such as Arvinas, Nurix Therapeutics, C4 Therapeutics, and innovative newcomers including Larkspur Bio, Magnet Biomedicine, TrimTech Therapeutics, as well as the co-founders of TPD, Craig Crews and Ray Deshaies, this was your ultimate meeting to hear the latest clinical data, forge strategic relationships, and capitalize on the huge opportunity for this modality to treat patients with high unmet clinical need.

In the rapidly advancing field of TPD research, this summit is an excellent opportunity to see a number of amazing cutting-edge approaches from academia, biotech and pharma.

Kazuteru Aoki, Vice President of Biology, FIMECS, Inc.

logo (5)

In a rapidly evolving drug development landscape, engaging with global experts at the TPD Summit is not just an opportunity—it’s a strategic imperative to validate and sharpen the competitive edge of our protein degrader platform.

Hyunson Jo, Founder and CEO, Pin Therapeutics

1622573510308

The TPD&IP Summit is THE meeting each year to learn from the best and brightest minds working on PROTACs, DACs, and molecular glues -- it is THE not-miss meeting to stay on top of this rapidly evolving field.

Brent Meadows, CBO, Polymed Bio

1719256208661

Official Partners 2025

Expertise Partner

Program Partners

Attending Companies Included

Join Biopharma Experts
Explore the 2025 Agenda

Hear the latest industry breakthroughs and gain exclusive insights on the TPD innovations during our packed agenda, interactive roundtables, and new CCOs & VC panel discussions.

Partner With Us
Partner With Us

Position yourself alongside as the leading solution provider to ensure your brand is at the heart of TPD biopharma deals.

Explore the Agenda
Join Biopharma Experts

Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.